+ Watch BCRX
on My Watchlist
A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.
In 2009 Biocryst wanted to be the H1N1 superhero, but in 2010 looks much more like an H1N1 survivor. The company emerges from the epidemic ravaged but alive, with nearly two thirds of their peak market cap melted away from their bones. The new 140M enterprise value seems much more in line with the current pipeline and potential. For the remainder of 2010, the company expects to report results from two phase II studies of forodesine in hematologic malignancies as well as from a phase II trial of the mysterious gout drug BCX4208. Meanwhile, the phase III trial of IV peramivir has begun enrolling patients in the Southern Hemisphere, where they insist on having winter when they should be enjoying summer.
GBMB buy of 3000 shares at 3.4 today.
Sold 3000 shares at 4.05 today for a GBMB profit of $1950. Could be another regretful sell but the jump today seemed kind of a stretch based on the strength of the catalyst. I expect more hard times ahead before the next swine flu epidemic.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions